Serum miRNA relevant to chronic heart failure and application of serum miRNA

A chronic heart failure, hsa-mir-665 technology, applied in the direction of DNA / RNA fragments, recombinant DNA technology, microbial measurement / inspection, etc., can solve the lack of detection and comparison of miRNAs in myocardial tissue, lack of epidemiological follow-up studies, etc. question

Active Publication Date: 2015-10-21
汪道文 +2
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether there is a class of miRNAs that have biomarker functions in the diagnosis and prognosis of chronic heart failure, and whether detection of such miRNAs can provide new strategies for the diagnosis and prognosis of chronic heart failure is still a challenge for researchers in this field
Some researchers have screened the expression profile of miRNAs in peripheral blood of patients with chronic heart failure (Circulation.2014; 129(9):1009-21; Proc Natl Acad Sci US A.2014; 111(30):11151-6), Some researchers have also detected the expression profile of miRNAs in peripheral blood of patients with chronic heart failure before and after treatment (Eur J Heart Fail.2013; 15(11):1277-88), but did not simultaneously conduct miRNAs in myocardial tissue and peripheral blood of the same patients. Detection and comparison, and lack of corresponding epidemiological follow-up studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serum miRNA relevant to chronic heart failure and application of serum miRNA
  • Serum miRNA relevant to chronic heart failure and application of serum miRNA
  • Serum miRNA relevant to chronic heart failure and application of serum miRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1. Screening results of miRNAs in peripheral blood and myocardial tissue of patients with chronic heart failure

[0026] 1. Collect peripheral blood samples from 10 cases of chronic heart failure (taken from inpatients in the Department of Cardiovascular Medicine from 2007 to 2014, each case was diagnosed and classified by two or more clinicians) and 10 normal controls. After sampling, centrifuge at 3,500 rpm for 6 minutes at room temperature, take the upper layer of plasma, and store it in a -80°C refrigerator. Add 1ml TRIZOL LS (Invitrogen Company) to every 0.25ml peripheral blood plasma, extract RNA, and RNasey Mini Kit (Qiagen) processes the sample. use ND-1000 detects RNA quality. miRCURY TM After being labeled with Array Power labeling kit (Exqion), the hybridization experiment was performed at the hybridization workstation. Axon GenePix 4000B microarray scanner scans to obtain chip images. GenePix pro V6.0 software analyzed the obtained data, and u...

Embodiment 2

[0029] Example 2. Analysis of miRNAs chip expression profile in peripheral blood and myocardial miRNAs chip expression profile in patients with chronic heart failure

[0030] The obtained microarray data were analyzed and processed by bioinformatics analysis methods.

[0031] 1. The scatter plot reflects the repeatability between chips or groups. The better the repeatability, the closer to the diagonal. In addition, the Pearson correlation coefficient was used to measure the repeatability, and the closer the correlation coefficient was to 1, the better the repeatability. Figure 1A with 1B The results show that the chips are finished with reliable quality and good repeatability.

[0032] 2. For comparison between groups, see Figure 1C with 1D . Use -log(Pvalue) as the ordinate and log2(Fold change) as the abscissa to plot each miRNA, and you can visually see the miRNAs with significant differences (gray dots represent miRNAs screened by Fold change and P-value) . Figur...

Embodiment 3

[0033] Example 3. Comparison of miRNAs expression profile in peripheral blood and myocardial tissue miRNAs expression profile

[0034] The trends of all miRNAs differentially expressed as candidate biomarkers for the diagnosis of chronic heart failure obtained from peripheral blood microarray and myocardial tissue microarray screening were classified. The results showed that there were 74 miRNAs with significant differences (including increase or decrease) in myocardial tissue expression, 599 miRNAs with significant differences (including increase or decrease) in peripheral blood, and 25 miRNAs with significant differences in expression (including increase or decrease). The expression of miRNAs in the two chips were all changed, and the expression of 6 miRNAs were all increased ( Figure 2A ) (hsa-miR-4491, hsa-miR-1285-3p, hsa-miR-665, hsa-miR-660-3p, hsa-miR-206 and hsa-miR-1268b), there were 2 species whose expression decreased ( Figure 2B ) (hsa-miR-130a-3p and hsa-miR-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides serum miRNA relevant to a chronic heart failure and application of the serum miRNA. The invention provides application of peripheral blood miRNAs to the chronic heart failure as biomarker risk assessment / diagnosis and prognosis. Hsa-miR-4491, hsa-miR-1285-3p, hsa-miR-665, hsa-miR-660-3p, hsa-miR-206, hsa-miR-1268b, hsa-miR-130a-3p and hsa-miR-330-3p have differential expressions in peripheral blood of heart failure patients. It is proved that the peripheral blood hsa-miR-665 and the like can perform specific diagnosis on the chronic heart failure, the expression level of the hsa-miR-665 and the like is relevant to ejection fraction, and the hsa-miR-665 has an assessment and prognosis effect. Thus, by detecting the expression level of the miRNAs, the existing chronic heart failure can be predicted and coordinately diagnosed, or prognosis of the chronic heart failure can be estimated.

Description

technical field [0001] The present invention relates to the new medical application of various endogenous non-coding small RNAs, more specifically to the application of 8 microRNAs in the diagnosis and prognosis evaluation of chronic heart failure, which belongs to the diagnosis, prevention and treatment of cardiovascular diseases field. Background technique [0002] Chronic heart failure is a clinical syndrome in which different cardiovascular diseases develop to the end stage. The main pathophysiological features are impaired ventricular filling and ejection ability, which eventually leads to low ventricular pumping function. It has a poor prognosis and high mortality. One of the most important causes of threats to human health and increased medical burden is especially important for China, which has an aging population. So far, the combination of therapeutic drugs based on diuretics, ACEI and β-receptor blockers is ineffective or unsatisfactory for some patients, and new...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/113
CPCC12Q1/6883C12Q2600/118C12Q2600/178
Inventor 汪道文陈琛李华萍
Owner 汪道文
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap